Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Exclusive: U.S. trial of AstraZeneca COVID-19 vaccine may resume this week - sources

10/20/2020 | 08:38pm EST
FILE PHOTO: A test tube labelled with the Vaccine is seen in front of AstraZeneca logo in this illustration taken

CHICAGO/WASHINGTON (Reuters) - AstraZeneca Plc COVID-19 vaccine trial in the United States is expected to resume as early as this week after the U.S. Food and Drug Administration completed its review of a serious illness in a study participant, four sources told Reuters.

AstraZeneca's large, late-stage U.S. trial has been on hold since Sept. 6, after a participant in the company's UK trial fell ill with what was suspected to be a rare spinal inflammatory disorder called transverse myelitis.

The sources, who were briefed on the matter but asked to remain anonymous, said they have been told the trial could resume later this week. It was unclear how the FDA would characterize the illness, they said.

An FDA spokeswoman declined to comment.

The agency is requiring researchers conducting the trial to add information about the incident to consent forms signed by study participants, according to one of the sources.

UK regulatory officials previously reviewed the illness and determined there was "insufficient evidence to say for certain" that it was or was not related to the vaccine. It permitted the trial to resume in the UK, according to a draft of the updated consent form shared with Reuters.

"In this case, after considering the information, the independent reviewers and MHRA (Medicines and Healthcare products Regulatory Agency) recommended that vaccinations should continue," the draft consent form stated. "Close monitoring of the affected individual and other participants will be continued."

Regulators in Brazil, India and South Africa also previously allowed AstraZeneca to resume its vaccine trials there.

AstraZeneca, which is developing the vaccine with Oxford University researchers, had been seen as a frontrunner in the race to produce a vaccine for COVID-19 until its trials were put on hold to investigate the illness. Early data from large-scale trials in the United States of vaccines from Pfizer Inc and Moderna Inc are expected some time next month.

Johnson & Johnson last week paused its Phase III COVID-19 vaccine trial to investigate an unexplained illness in a study participant. At the time of the announcement, the company did not know whether the volunteer had been given its vaccine or a placebo.

A J&J spokesman on Tuesday said the study remains on pause as the company continues its review of medical information before deciding to restart the trial. J&J noted last week that its "study pause" was voluntary. By contrast, AstraZeneca's trial is on "regulatory hold," which is imposed by health authorities.

Vaccines are seen as essential to helping end the pandemic that has battered economies around the world and claimed more than 1 million lives - over 220,000 of them in the United States.

Responding to a request about the AstraZeneca trial, British regulators shared with Reuters a draft of a form letter to UK vaccine trial participants, dated Oct. 14 and signed by the Oxford COVID-19 Vaccine Team. It says the U.S. FDA had "completed their analysis" and said vaccination under the study in the United States would resume shortly.

FDA "has come to the same conclusion as the other drug regulators including the MHRA," the letter states.

The Health Research Authority, which helps oversee UK medical research, said in an email to Reuters that it vetted the communication to make sure it was suitable to ensure informed consent among study volunteers. It could not confirm that the letter had been issued.

An AstraZeneca spokeswoman said the communication is not from the company and it "cannot verify the content," referring to the draft letter to study participants.

"We also cannot comment on a pending FDA decision," she said. The Oxford study team did not respond to requests for comment.

NOT ENOUGH EVIDENCE

In another of the documents directed at trial participants, the Oxford vaccine study team noted that there was not enough evidence to link the neurological problem seen in the UK trial to the vaccine.

Dr. Paul Offit, director of the Vaccine Education Center at Children's Hospital of Philadelphia, who reviewed the document, said it can be difficult to link a rare side effect specifically to a vaccine to the exclusion of other potential causes.

Transverse myelitis, which the study volunteer is believed to have developed, typically occurs at a rate of 1-in-200,000 people, Offit said, so it would be unusual to see it in a trial of 9,000 individuals.

Other viruses including those that cause West Nile and polio can trigger the condition, as can physical trauma.

The regulators have to weigh whether a rare side effect is vaccine-related and could occur again against the sickness and deaths linked with COVID-19, Offit said. "That's always the line that you walk."

(Reporting by Julie Steenhuysen and Marisa Taylor; Editing by Bill Berkrot and Leslie Adler)

By Julie Steenhuysen and Marisa Taylor


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.28% 7770 Delayed Quote.2.14%
DOW JONES AFRICA TITANS 50 INDEX -1.06% 501.92 Delayed Quote.-5.57%
DOW JONES SOUTH AFRICA(ZAR) -0.64% 1728.26 Delayed Quote.-4.21%
EURO / BRAZILIAN REAL (EUR/BRL) 0.54% 6.3746 Delayed Quote.40.72%
MODERNA, INC. 16.35% 127.03 Delayed Quote.549.44%
PFIZER INC. 1.92% 37.23 Delayed Quote.0.30%
S&P AFRICA 40 INDEX -0.87% 162.67 Delayed Quote.-5.02%
All news about ASTRAZENECA PLC
11:22aSerum Institute CEO sees AstraZeneca's COVID-19 vaccine as "very good" candid..
RE
11:18aSerum Institute CEO sees AstraZeneca's COVID-19 vaccine as "very good" candid..
RE
10:59aUK regulator set to approve COVID-19 vaccine next week - FT
RE
10:31aIndia's Modi visits key vaccine facilities as COVID-19 cases surge
RE
08:22aUK appoints vaccines minister to oversee COVID inoculations
AQ
08:05aIndia's Modi visits key vaccine facilities as COVID-19 case load surges
RE
03:32aOil prices post weekly gain ahead of OPEC+ meeting
RE
11/27SALESFORCE, DELTA AIR LINES, BEST BU : Stocks That Defined the Week
DJ
11/27Stocks at record high but yields fall, dollar under pressure
RE
11/27Oil prices post weekly gain ahead of OPEC+ meeting
RE
More news
Financials (USD)
Sales 2020 26 512 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 43,5x
Yield 2020 2,72%
Capitalization 136 B 136 B -
EV / Sales 2020 5,62x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121,49 $
Last Close Price 103,45 $
Spread / Highest target 50,3%
Spread / Average Target 17,4%
Spread / Lowest Target -36,2%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC2.14%135 908
DAIICHI SANKYO COMPANY, LIMITED56.60%72 682
JIANGSU HENGRUI MEDICINE CO., LTD.17.92%69 850
YUNNAN BAIYAO GROUP CO.,LTD7.23%18 673
ORION OYJ-3.10%6 712
SWEDISH ORPHAN BIOVITRUM AB1.42%5 440